BioTuesdays

Category - Markets

GlycoMimetics

HCW starts GlycoMimetics at buy; PT $24

H.C. Wainwright launched coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and $24 price target based on a positive outlook for the company’s pipeline. The stock closed at $10.29 on Dec. 17...

Novavax Logo

Ladenburg starts Novavax at buy; PT $3

Ladenburg Thalmann initiated coverage of Novavax (NASDAQ:NVAX) with a “buy” rating and $3 price target, as “we look for transformational data in the first quarter of 2019.” The stock closed at $2.27 on Dec. 17. Novavax...

Advaxis Logo

HCW cuts Advaxis to neutral and removes PT

H.C. Wainwright downgraded Advaxis (NASDAQ:ADXS) to “neutral” from “buy” and removed its price target after Amgen terminated a development and collaboration agreement on ADXS-NEO, Advaxis’ personalized neoantigen...

CollPlant

Roth starts CollPlant at buy; PT $7

Roth Capital Markets launched coverage of CollPlant Holdings (NASDAQ:CLGN) with a “buy” rating and 12-month price target of $7. The stock closed at $4.36 on Dec. 17. CollPlant is the world’s first and only commercial...

Arch Therapeutics

Roth ups Arch Therapeutics PT to $3 from $2.10

Roth Capital Partners raised its price target for Arch Therapeutics (OTCQB:ARTH) to $3 from $2.10 after the FDA cleared the company’s AC5 Topical Gel for use in partial and full-thickness skin wounds, such as pressure...

Millendo Therapeutics

Leerink starts Millendo at OP; PT $24

Leerink Partners launched coverage of Millendo Therapeutics (NASDAQ:MLND) with an “outperform” rating and $24 price target. The stock closed at $9.64 on Dec. 12. Millendo is developing treatments for rare, debilitating...

DarioHealth

AGP starts DarioHealth at buy; PT $2.50

AGP/Alliance Global Partners initiated coverage of DarioHealth (NASDAQ:DRIO) with a “buy” rating and price target of $2.50. The stock closed at 76 cents on Dec. 12. ”DarioHealth is well positioned at the confluence of...